Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.

Array of blood samples for microscopy and biopsy tissue on blue gradient background

Guardant Health, Inc. CEO Helmy Eltoukhy described the recent US Food and Drug Administration approval of the company’s liquid biopsy test Guardant360 CDx as a “watershed moment for comprehensive liquid biopsy” because it provides oncologists with the information they need to close the gap between clinical guidelines and clinical practice.

The Redwood City, CA-based liquid biopsy company announced on 7 August that its Guardant360 assay was approved for comprehensive tumor...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from In Vitro Diagnostics

More from Diagnostics